Antidepressant medication may prevent recurring depression in diabetics

May 01, 2006

The antidepressant sertraline may reduce the risk of recurrent depression and increase the period of time between episodes of depression in patients with diabetes, according to a study in the May issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

One of every four patients with diabetes experiences clinical depression, according to background information in the article. Among those with diabetes, depression can reduce quality of life and the ability to function and increase the risk for high blood sugar levels, diabetes-related complications and death. Treatment with antidepressant medications and psychotherapy has been shown to be effective, but only in the short term. In previous studies, one in seven patients with diabetes developed recurrent depression that did not respond to treatment and their blood sugar levels generally increased, placing them at a higher risk of complications associated with their diabetes.

Patrick J. Lustman, M.D., Washington University School of Medicine, St. Louis, and colleagues studied 152 patients with diabetes (average age 52.8 years) who had recovered from depression during treatment with sertraline. Participants were followed for up to one year or until their depression recurred, during which time 79 were randomly assigned to continue taking sertraline and 73 were randomly assigned to take a placebo. They visited a physician's office every month and received phone calls at the two-week point to screen for symptoms of depression. If such symptoms were detected, they underwent a psychiatric interview. Patients' hemoglobin (Hb A1c) levels, which reflect the individual's control of blood glucose levels over the previous two to three months, were measured every two months.

Participants taking sertraline were significantly less likely to develop an additional episode of depression. After one year, 65.8 percent of the patients taking sertraline remained in remission from their depression, compared with 47.9 percent of those taking placebo. The amount of time that passed before depression recurred in one-third of the patients increased from 57 days among patients receiving placebo to 226 days among those taking sertraline. "Using data available at the one-year point, the number needed to be treated was six patients, i.e., it would be necessary to treat six patients to spare one patient from depression recurrence," the authors write. All participants' Hb A1c levels had decreased when they recovered from depression and remained lower as long as they remained depression-free, with no difference between the two study groups.

Depression is increasingly understood as a recurrent and debilitating disease, especially for those with diabetes, the authors write. Physicians suspect that the more time an individual spends depressed, the greater the risk for diabetic complications and death. "Our study establishes a clear benefit of sertraline for prevention of depression recurrence in patients with diabetes," they conclude. "Sertraline lengthened the depression-free interval of maintenance and did not interfere with glycemic improvement achieved during the recovery phase. Treatment with sertraline is relatively simple, safe and widely available, and although it is not curative, it offers patients with diabetes a potentially viable method for ameliorating the suffering, incapacity and burden associated with recurrent depression."
-end-
(Arch Gen Psychiatry. 2006;63:521-529. Available pre-embargo to journalists at www.jamamedia.org)

Editor's Note: This study was supported in part by grants from the National Institutes of Health, Bethesda, Md., and an unrestricted educational grant from Pfizer, Inc., New York.

The JAMA Network Journals

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.